Phase I study of tricyclic nucleoside phosphate

Cancer Treat Rep. 1983 Feb;67(2):159-62.

Abstract

A phase I study of tricyclic nucleoside phosphate was conducted in 20 adults with advanced cancer. Tricyclic nucleoside phosphate was given as an iv infusion over 15 minutes once every 3 weeks; the doses ranged from 25 to 350 mg/m2. Beginning at a dose of 250 mg/m2, hyperglycemia and elevation of hepatocellular enzymes were observed; at a dose of 350 mg/m2, two patients developed irreversible liver damage. Patients at all dose levels experienced reduction in serum phosphorus; reduction of serum calcium was noted only with the two highest doses. Nausea and vomiting occurred occasionally. Myelosuppression was not a prominent toxic effect. No major therapeutic responses were noted. Further clinical trials employing this schedule are probably not warranted.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acenaphthenes
  • Adult
  • Aged
  • Blood Glucose
  • Bone Marrow / drug effects
  • Calcium / blood
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Humans
  • Infusions, Parenteral
  • Liver / enzymology
  • Male
  • Middle Aged
  • Nausea / chemically induced
  • Neoplasms / drug therapy*
  • Phosphorus / blood
  • Ribonucleotides / adverse effects
  • Ribonucleotides / therapeutic use*

Substances

  • Acenaphthenes
  • Blood Glucose
  • Ribonucleotides
  • Phosphorus
  • triciribine phosphate
  • Calcium